CN115698048A - 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 - Google Patents

用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 Download PDF

Info

Publication number
CN115698048A
CN115698048A CN202180022864.1A CN202180022864A CN115698048A CN 115698048 A CN115698048 A CN 115698048A CN 202180022864 A CN202180022864 A CN 202180022864A CN 115698048 A CN115698048 A CN 115698048A
Authority
CN
China
Prior art keywords
mydgf
heart failure
variant
fragment
hypertrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180022864.1A
Other languages
English (en)
Chinese (zh)
Inventor
卡伊·克里斯托夫·沃勒特
莫蒂默·科尔夫-克林格比尔
马克·R·雷博拉
安东·佩克切克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN115698048A publication Critical patent/CN115698048A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180022864.1A 2020-01-21 2021-01-19 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 Pending CN115698048A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20153008 2020-01-21
EP20153008.6 2020-01-21
PCT/EP2021/051079 WO2021148411A1 (en) 2020-01-21 2021-01-19 Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure

Publications (1)

Publication Number Publication Date
CN115698048A true CN115698048A (zh) 2023-02-03

Family

ID=69187588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180022864.1A Pending CN115698048A (zh) 2020-01-21 2021-01-19 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子

Country Status (12)

Country Link
US (1) US20230059560A1 (https=)
EP (1) EP4093750A1 (https=)
JP (1) JP7777532B2 (https=)
KR (1) KR20220131262A (https=)
CN (1) CN115698048A (https=)
AU (1) AU2021211874A1 (https=)
BR (1) BR112022014272A2 (https=)
CA (2) CA3164500A1 (https=)
MX (1) MX2022008727A (https=)
PH (1) PH12022551792A1 (https=)
TW (1) TW202142254A (https=)
WO (1) WO2021148411A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022066729A1 (en) * 2020-09-22 2022-03-31 Wisconsin Alumni Research Foundation Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor
US20250325704A1 (en) 2020-12-23 2025-10-23 Boehringer Ingelheim International Gmbh Viral capsid proteins with specificity to heart tissue cells
CN115820829B (zh) * 2022-03-22 2026-04-17 中国人民解放军军事科学院军事医学研究院 Mydgf在防治记忆损伤及其相关疾病中的应用
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
JP2025530232A (ja) 2022-09-08 2025-09-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心原性ショックの処置に用いる骨髄由来成長因子
EP4480490A1 (en) * 2023-06-23 2024-12-25 Medizinische Hochschule Hannover Brick1 for use in treating myocardial diseases
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202539726A (zh) 2023-12-06 2025-10-16 德商百靈佳殷格翰國際股份有限公司 包含骨髓衍生性生長因子之新穎調配物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
CN104968361A (zh) * 2013-01-17 2015-10-07 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
WO2019217715A1 (en) * 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
AU717542B2 (en) 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
JP2001506484A (ja) 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US20080004232A1 (en) 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP2130547A1 (en) 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
WO2020176732A1 (en) * 2019-02-27 2020-09-03 Icahn School Of Medicine At Mount Sinai TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
CN104968361A (zh) * 2013-01-17 2015-10-07 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
CN110894226A (zh) * 2013-01-17 2020-03-20 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
WO2019217715A1 (en) * 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERT G GOURDIE等: "Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease", NAT REV DRUG DISCOV., 24 June 2016 (2016-06-24), pages 620 - 638 *
郭晓;王肖龙;汤仁智;孙元隆;李益萍;肖正达;阮小芬;: "可溶性基质裂解素2和脑利钠肽对射血分数保留型心力衰竭诊断的临床意义", 中国医药导报, no. 15, 25 May 2020 (2020-05-25) *

Also Published As

Publication number Publication date
PH12022551792A1 (en) 2023-09-18
EP4093750A1 (en) 2022-11-30
MX2022008727A (es) 2022-10-07
CA3164500A1 (en) 2021-07-29
AU2021211874A1 (en) 2022-08-25
WO2021148411A1 (en) 2021-07-29
JP7777532B2 (ja) 2025-11-28
KR20220131262A (ko) 2022-09-27
TW202142254A (zh) 2021-11-16
JP2023511358A (ja) 2023-03-17
US20230059560A1 (en) 2023-02-23
CA3223879A1 (en) 2021-07-29
BR112022014272A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
CN115698048A (zh) 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子
AU2020267282B2 (en) Compositions and methods for decreasing tau expression
KR102712656B1 (ko) Hsd17b13 변종 및 이것의 용도
RU2745324C2 (ru) Композиции и способы модулирования экспрессии tau
CN115181778A (zh) 选择治疗性分子的方法
KR102723469B1 (ko) 타우 발현을 조절하기 위한 올리고뉴클레오티드
JP2016516423A (ja) 心筋症を処置するための遺伝子治療ベクター
KR102520654B1 (ko) 안티센스 올리고뉴클레오티드 및 당원병 Ia형 예방 또는 치료용 조성물
KR20120099363A (ko) 탯줄 혈액으로부터의 유도 만능 줄기 세포의 생성
CN111032093A (zh) 控制心肌纤维化和重塑的方法和组合物
JPWO2004022753A1 (ja) アクチン関連新規細胞骨格タンパク質ｌａｃｓ
TW202313974A (zh) 用於治療肝病之組合療法
CN110167563A (zh) 用于调节心脏细胞功能的方法、相关核苷酸和化合物
WO2003014340A2 (en) Human histone deacetylase-related gene and protein hdac10
HK40088501A (zh) 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子
WO2024213890A1 (en) Oligonucleotide decoy
CN113966341B (zh) Sghrt编码的多肽及相关产物、方法和用途
KR102460983B1 (ko) 새로운 재생 치료제로서의 camkk1
EA053022B1 (ru) Фактор роста миелоидного происхождения для применения при лечении или профилактике фиброза, гипертрофии или сердечной недостаточности
KR20240149152A (ko) 안티센스 올리고뉴클레오티드 및 당원병 Ia형 예방 또는 치료용 조성물
HK40105813A (zh) 用於治疗肝病的组合疗法
RU2777570C2 (ru) Композиции и способы для снижения экспрессии tau

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088501

Country of ref document: HK